title: Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo.
abstract: BACKGROUND
  Pharmacotherapy, associated with a comprehensive weight loss intervention, has emerged as a promising therapeutic approach in adolescents. Identification of subjects who best respond to a pharmacological intervention remains difficult.
  
  
  OBJECTIVE
  To compare the value of early weight loss after 12 weeks of treatment with placebo or orlistat (120 mg three times a day) in predicting treatment outcome after 52 weeks.
  
  
  METHODS
  Secondary analysis of a randomized control trial in 182 placebo-treated and 357 orlistat-treated obese adolescents (Body mass index [BMI] ≥ 2 kg/m(2) above the 95(th) percentile).
  
  
  RESULTS
  Percent weight change at 12 weeks was positively correlated with percent change in weight (r(2) ≥ 0.41), BMI (r(2) ≥ 0.33) and waist circumference (r(2) ≥ 0.20) at 52 weeks in both the placebo and orlistat groups (P < 0.001). A weight loss ≥ 5% of baseline weight at 12 weeks was associated with a mean weight loss of 8.1% (95% CI: 6.4 to 9.7) at the study end that was independent of treatment. Subjects in the orlistat group were 2.44 times (95% CI: 1.34 to 4.46) more likely to experience a weight loss ≥ 5% after 12 weeks than subjects in the placebo group (P = 0.0028).
  
  
  CONCLUSIONS
  Early weight loss predicts a favourable outcome in both placebo-treated and orlistat-treated subjects but is more than 2 times more likely to occur in the orlistat group. Addition of orlistat should be considered as part of a weight loss intervention but reevaluated after 3 months of treatment.
authors.affiliation: Endocrinology and Diabetes Unit, British Columbia Children's Hospital, University of British Columbia, Vancouver, Canada. jchanoine@cw.bc.ca
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Chanoine
authors.forename: Matthew
authors.initials: M
authors.lastname: Richard
mesh_terms: D000293:Adolescent; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D015992:Body Mass Index; D005260:Female; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D009765:Obesity / Q000188:drug therapy*; D000077403:Orlistat; D012189:Retrospective Studies; D016037:Single-Blind Method; D016896:Treatment Outcome; D015431:Weight Loss
chemical_list: D019440:Anti-Obesity Agents; D007783:Lactones; D000077403:Orlistat